Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial

We have carried out the largest randomised trial to date of newly diagnosed myeloma patients, in which lenalidomide has been used as an induction and maintenance treatment option and here report its impact on second primary malignancy (SPM) incidence and pathology. After review, 104 SPMs were confir...

Descripción completa

Detalles Bibliográficos
Autores principales: Jones, J R, Cairns, D A, Gregory, W M, Collett, C, Pawlyn, C, Sigsworth, R, Striha, A, Henderson, R, Kaiser, M F, Jenner, M, Cook, G, Russell, N H, Williams, C, Pratt, G, Kishore, B, Lindsay, J, Drayson, M T, Davies, F E, Boyd, K D, Owen, R G, Jackson, G H, Morgan, G J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5223149/
https://www.ncbi.nlm.nih.gov/pubmed/27935580
http://dx.doi.org/10.1038/bcj.2016.114

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5223149/
https://www.ncbi.nlm.nih.gov/pubmed/27935580
http://dx.doi.org/10.1038/bcj.2016.114

Ejemplares similares